Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMONTASTRUC, François
dc.contributor.authorBENEVENT, J.
dc.contributor.authorTOUAFCHIA, A.
dc.contributor.authorCHEBANE, L.
dc.contributor.authorARAUJO, M.
dc.contributor.authorGUITTON-BONDON, E.
dc.contributor.authorDURRIEU, G.
dc.contributor.authorARBUS, C.
dc.contributor.authorSCHMITT, L.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
dc.contributor.authorMONTASTRUC, J. L.
dc.date.accessioned2020-12-08T13:07:28Z
dc.date.available2020-12-08T13:07:28Z
dc.date.issued2018-02
dc.identifier.issn1472-8206 (Electronic) 0767-3981 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/21358
dc.description.abstractEnAntipsychotic drugs possess side atropinic (anticholinergic) properties that may induce several adverse drug reactions (ADRs), such as memory loss or cognitive impairment. The aim of the present study was investigating anticholinergic burden in patients treated with antipsychotic drugs. All ADR reports including at least one antipsychotic and registered between 2000 and 2015 in the Midi-Pyrenees PharmacoVigilance Database were extracted and analyzed using the Anticholinergic Duran's list. The primary objective of this cross-sectional study was to calculate anticholinergic burden in antipsychotic-treated patients; the secondary one was to investigate associated factors. Among the 1,948 reports, the average number of atropinic drugs per report was 2.4 +/- 1.4. At least one atropinic drug was found in 59.4% of reports (1,158), in addition to antipsychotic drugs. The mean anticholinergic burden per report was 3.9 +/- 2.9. A value >/= 3 was found in 61.7% of the reports. A significant association between anticholinergic burden, age and male gender of patients was found. The mean value of anticholinergic burden remained stable during the study period. This study showed high values of anticholinergic burden in patients receiving antipsychotics. Thus, considering the potential noxious clinical impact of atropinic properties on cognitive functions, an appropriate approach should be to reduce prescription of antipsychotics with a high anticholinergic burden but also coprescription of other frequently associated atropinic drugs, like antiparkinsonians, H1 antihistamines or imipraminic antidepressants in these patients.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enAtropinic (anticholinergic) burden in antipsychotic-treated patients
dc.title.alternativeFundam Clin Pharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/fcp.12321en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed28887902en_US
bordeaux.journalFundamental and Clinical Pharmacologyen_US
bordeaux.page114-119en_US
bordeaux.volume1en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03193860
hal.version1
hal.date.transferred2021-04-09T08:15:10Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Fundamental%20and%20Clinical%20Pharmacology&rft.date=2018-02&rft.volume=1&rft.spage=114-119&rft.epage=114-119&rft.eissn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.issn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.au=MONTASTRUC,%20Fran%C3%A7ois&BENEVENT,%20J.&TOUAFCHIA,%20A.&CHEBANE,%20L.&ARAUJO,%20M.&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record